RTP Mobile Logo
Breast Cancer Update: Surgical Edition, Issue 1, 2019 (Video Program)
Released October 2019

Featuring interviews with Drs Charles E Geyer Jr and Tari A King. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for breast and general surgeons, surgical oncologists, surgical fellows and other healthcare providers involved in the treatment of breast cancer.

    Breast cancer continues to be one of the most rapidly evolving fields in medical oncology. Historically, surgery has been the primary mode of treatment for localized breast cancer. The complexity of the diagnostic, surgical and medical management of this disease, however, has escalated because of numerous advances in novel technologies and available adjunctive therapies. Hence, the multifaceted treatment of breast cancer now requires the input of an interdisciplinary group of expert care providers, and this paradigm shift has created the challenge of ensuring that knowledge of major clinical advances in local and systemic therapy is effectively disseminated among all members of the cross-functional team. To bridge the gap between research and patient care, Breast Cancer Update for Surgeons uses one-on-one interviews with leading breast cancer investigators to efficiently distill the latest research developments so they may be incorporated into clinical practice as appropriate. By providing access to cutting-edge data and expert perspectives, this CME program assists breast surgeons in the formulation of up-to-date clinical management strategies.


    • Recognize the evolving application of biomarkers and multigene assays in breast cancer management, and effectively use these tools to refine or individualize treatment plans for patients with localized disease.
    • Appreciate the role of adjuvant endocrine therapy alone versus chemoendocrine therapy for women with ER-positive, HER2-negative, node-negative breast cancer and an intermediate 21-gene Recurrence Score®.
    • Implement a long-term clinical plan for the management of early-stage HER2-positive breast cancer, incorporating existing, recently approved and emerging targeted treatments.
    • Develop an evidence-based approach to management of the axilla for patients with localized breast cancer and a positive sentinel lymph node biopsy.
    • Individualize the selection of treatment for patients with hormone receptor-positive breast cancer, including consideration of endocrine, biologic and chemotherapeutic agents.
    • Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Charles E Geyer Jr, MD
    Professor of Medicine
    Virginia Commonwealth University School of Medicine
    Harrigan, Haw, Luck Families Chair in Cancer Research
    Associate Director of Clinical Research
    Massey Cancer Center
    Richmond, Virginia

    Advisory Committee: Celgene Corporation, Daiichi Sankyo Inc, Genentech, Roche Laboratories Inc; Contracted Research: Genentech, Merck.

    Tari A King, MD
    Associate Chair for Multidisciplinary Oncology
    Department of Surgery
    Chief, Division of Breast Surgery
    Brigham and Women’s Hospital
    Dana-Farber/Brigham and Women’s Cancer Center
    Anne E Dyson Associate Professor of Surgery
    Harvard Medical School
    Boston, Massachusetts

    Speakers Bureau: Genomic Health Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Genomic Health Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: October 2019
    Expiration date: October 2020

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Interview with Charles E Geyer Jr, MD

Interview with Tari A King, MD

Select Publications